It is made available under a CC-BY 4.0 International license .

1	Factors affecting antenatal corticosteroid use in low- and middle-income countries: facility
2	characteristics, structural readiness, and past performance of CEmONC signal functions
3	
4	Author information
5	Wen-Chien Yang (0000-0001-8206-1496) ^{1*} ; Catherine Arsenault (0000-0003-2410-3015) ¹ ;
6	Victoria Y. Fan (0000-0001-7755-9425) ² ; Nazia Binte Ali (0000-0001-5010-9563) ³ ;
7	Fadhlun Mohamed Alwy Al-beity (0000-0003-2416-6876) ⁴ ; Emily R. Smith (0000-0001-5715-
8	9459) ^{1, 5}
9	
10	1. Department of Global Health, Milken Institute School of Public Health, The George
11	Washington University, Washington, DC, USA
12	2. Center for Global Development, Washington, DC, USA
13	3. Department of Global Health and Population, Harvard T.H. Chan School of Public Health,
14	Boston, Massachusetts, USA
15	4. Muhimbili University of Health and Allied Science, Dar es Salaam, Tanzania
16	5. Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The
17	George Washington University, Washington, DC, USA
18	
19	
20	Word count: 3062
21	Abstract word count: 300
22	Number of figures and tables: 4
23	

It is made available under a CC-BY 4.0 International license .

- 24 *Corresponding Author: Wen-Chien Yang, MD, MPH
- 25 Address: 950 New Hampshire Ave, NW, Washington DC, 20037
- 26 Telephone: 617-794-2209
- 27 Email: wenchienyang@gwmail.gwu.edu

- -

It is made available under a CC-BY 4.0 International license .

47 ABSTRACT

48 Background

49 Antenatal corticosteroids (ACS) utilization is disproportionately limited in low- and middle-

50 income countries where most global preterm newborns who could benefit from this intervention

51 are born. Understanding the factors affecting ACS use is crucial for improving its uptake. This

52 study aimed to investigate facility-level factors associated with ACS use in low-resource

53 countries.

54 Methods

55 We used data from ten Service Provision Assessment surveys across nine countries. We 56 restricted the sample to facilities that provided delivery services. Our primary outcome was 57 recent ACS use, defined as having administered ACS within the past three months before the survey. We conducted mixed-effect log binomial regressions, with country as a fixed effect and 58 59 sub-national regions as random intercepts, to explore the association between recent ACS use 60 and facility characteristics, injectable corticosteroids and ultrasound availability, facility 61 structural readiness, and past performance of nine Comprehensive Emergency Obstetric and 62 Newborn Care (CEmONC) signal functions.

63 Results

64 This study included 6183 facilities from nine countries. Across eight countries with nationally

representative data, only 22.7% (median, range 4.0% to 27.4%) of facilities that provided

66 delivery services had used ACS recently. Urban facilities had a 21% higher likelihood of recent

67 ACS use (95% CI 6%–38%) than rural facilities. Corticosteroid availability was associated with

68 a 14% higher likelihood of recent ACS use (95% CI 1%–29%). Facilities in the highest readiness

69 tertile were more likely to have recent ACS use than those in the lowest (RR 1.91, 95% CI 1.58–

It is made available under a CC-BY 4.0 International license .

70	2.30). Each CEmONC signal function, except for assisted vaginal deliveries, was significantly
71	associated with recent ACS use, with neonatal resuscitation having the largest effect (RR 2.62,
72	95% CI 1.93–3.55).
73	Conclusion
74	Facilities that had performed CEmONC services were more likely to administer ACS,
75	highlighting the importance of provider knowledge, skills, and competence in managing obstetric
76	and newborn emergencies for effective ACS provision.
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	

It is made available under a CC-BY 4.0 International license .

93 INTRODUCTION

94 Administering antenatal corticosteroids (ACS) to pregnant women with a high likelihood of preterm labor at gestational age (GA) 24 to 34 weeks is recommended by the World Health 95 96 Organization (WHO) and major medical associations. (1-4) By accelerating fetal lung maturity, 97 this intervention effectively reduces neonatal mortality and morbidity, particularly respiratory 98 complications.(5) ACS use has been encouraged in low- and middle-income countries (LMICs), 99 where 80% of preterm births occur globally.(6) However, its uptake remains limited in these 100 countries. The WHO Born Too Soon report suggested prioritizing existing highly effective 101 interventions, including ACS.(7) The International Federation of Gynecology and Obstetrics also 102 listed ACS use among its PremPrep-5 initiative of effective and low-cost interventions to 103 improve preterm outcomes.(8) Therefore, a thorough understanding of factors associated with 104 low ACS use in LMICs is urgently needed. 105 Factors affecting ACS use in low-resource countries are complex.(9) These factors can be 106 primarily grouped into several levels. At the national level, guidelines and policies on ACS use 107 are fundamental. Previous studies have identified limited, unclear, or inconsistent national 108 guidelines as major obstacles.(9-12) The 2023 WHO Model List of Essential Medicines includes 109 dexamethasone, one of the two antenatal corticosteroids, under medicines for reproductive health 110 and perinatal care.(13) A study assessing barriers to ACS use found that the absence of ACS 111 from National Essential Medicines Lists was a significant barrier in half of the twelve African 112 and Asian countries examined.(11) Another policy analysis for seven sub-Saharan countries 113 showed that although most countries included ACS use in their national protocols, details on 114 accurate GA assessment and criteria for identifying eligible women were often unclear.(12) At 115 the facility level, poor healthcare quality—attributed to various factors, such as insufficient

It is made available under a CC-BY 4.0 International license .

116 medicines and equipment for maternal and newborn care and lack of integration of ACS into 117 regular perinatal care—hinders appropriate ACS use.(9, 11) At the individual level, providers' 118 knowledge gaps in ACS use and identifying preterm labor hinder its proper use. (9, 14, 15). 119 Pregnant women, also at the individual level, may lack access to this intervention due to their 120 underlying socioeconomic constraints; among those who have access, their perceptions of risks 121 and benefits also affect ACS use.(9) Hence, untangling the complexity of factors affecting ACS 122 use is critical for identifying priority actions. 123 Appropriate settings for safe and effective ACS use are challenging to define. The WHO 124 recommends giving ACS when the following conditions are met: accurate GA assessment, a high 125 likelihood of imminent preterm labor, no clinical maternal infections, and adequate childbirth 126 and preterm newborn care available.(1) However, implementing some of these recommendations 127 in low-resource settings poses practical challenges, raising discussions in the global 128 community.(8, 16, 17) Facilities that can perform Comprehensive Emergency Obstetric and 129 Newborn Care (CEmONC) are considered appropriate settings for administering ACS.(1, 11) 130 Basic Emergency Obstetric and Newborn Care (BEmONC) includes a set of seven signal 131 functions; CEMONC includes all BEMONC services and adds two additional functions: 132 Cesarean section and blood transfusion.(18) This set of health services defines the capability of a 133 facility to manage obstetric and newborn emergencies (19, 20), and health facilities in LMICs are 134 designated as a BEMONC or CEMONC facility based on their capabilities.(18) It is important to 135 note that many pregnant women who present with obstetric emergencies and require CEmONC 136 services are likely to deliver preterm babies. While managing maternal emergencies, it is as 137 crucial for providers to take a holistic approach and simultaneously implement interventions that 138 improve preterm outcomes, such as administering antenatal corticosteroids. A study comparing

It is made available under a CC-BY 4.0 International license .

indices to measure facility readiness noted that the past performance of CEmONC signal
functions reflected a certain or minimally required level of inputs available and provider
competence in managing obstetric emergencies.(21) However, no studies have examined the
relationships between health facilities' abilities to perform CEmONC signal functions and ACS
utilization.

- 144 This study aimed to assess the complex relationships among ACS utilization, facility
- 145 characteristics, corticosteroid and ultrasound availability, structural readiness, and the past
- 146 performance of CEmONC signal functions.

147 METHODS

148 Study sample

- 149 We used Service Provision Assessment (SPA) health facility survey data from nine LMICs (ten
- surveys).(22) Our sample included three countries from Asia (Afghanistan 2018-2019,
- 151 Bangladesh 2017-2018, Nepal 2021), one from the Caribbean (Haiti 2017-2018), and five from
- sub-Saharan Africa (the Democratic Republic of Congo (DRC) 2017-2018, Ethiopia 2021-2022,
- 153 Malawi 2013-2014, Senegal 2018 and 2019, and Tanzania 2014-2015). We had previously
- 154 conducted a study examining antenatal corticosteroid utilization in LMICs using the same
- data.(23) Most surveys employed a stratified random sampling strategy; some were national
- 156 censuses. Unlike other surveys, the Afghanistan 2018-2019 survey primarily sampled urban
- 157 hospitals. Since Senegal implemented continuous SPA over five consecutive years (24), we
- 158 merged the 2018 and 2019 Senegal SPA data to achieve a comparable sample size to other
- surveys and to be consistent with our previous work.(23) The SPA questionnaire has five
- 160 instruments, of which this study used data from the inventory instrument. We restricted our
- 161 analyses to facilities that provided delivery services (normal delivery and/or Cesarean sections).

It is made available under a CC-BY 4.0 International license .

162 *Measures*

163 The primary outcome was recent ACS use at the facility level, defined as having administered 164 ACS within the past 3 months before the survey. Administering ACS within this timeframe was 165 believed to reflect the facility's functionality at the time of the survey.(18) We identified three 166 main groups of facility-level factors to explore their relationships with recent ACS use. First, we 167 included facility characteristics such as location (urban versus rural) and managing authority 168 types. Because surveys used different groupings for managing authority types, we developed a 169 standardized categorization with four groups (public, private for-profit, private not-for-170 profit/mission or faith-based, and others) (Supplemental Table 1). Second, we identified 28 171 items essential for safe and effective ACS use based on the WHO recommendations, which 172 could be grouped into four major categories: equipment, diagnostics, medicines and 173 commodities, and guidelines (1); we used these items to develop facility structural readiness 174 (Supplemental Table 2). Based on the number of available items, we developed facility 175 readiness tertiles that were country-specific to account for the vastly different contexts and 176 survey years spanning from 2013 to 2021. A functional ultrasound was included separately 177 because access to ultrasound in early pregnancy is crucial for accurate GA dating. The measure 178 of a functional ultrasound was based on its availability in a health facility in general. The 179 availability of at least one valid corticosteroid (injectable betamethasone or dexamethasone) was 180 also included separately. However, we used its availability in the medicines for non-181 communicable diseases as a proxy because SPA does not survey corticosteroid availability in the 182 maternal and newborn care section. We adopted the same approach as our previous study.(23) 183 Additionally, we constructed several binary variables that indicated having at least one medical 184 doctor, midwife, obstetrician/gynecologist, pediatrician, or specialist. Countries surveyed staff

It is made available under a CC-BY 4.0 International license .

185 types in various ways of grouping. All countries surveyed the availability of medical doctors and 186 midwives. Six countries (Afghanistan, Haiti, DRC, Malawi, Senegal, and Tanzania) assessed the 187 availability of specialists in general but not specifically obstetricians/gynecologists or 188 pediatricians. Conversely, three countries (Bangladesh, Nepal, and Ethiopia) collected data on 189 the availability of obstetricians/gynecologists and pediatricians but not specialists. We used this 190 data to construct a binary variable indicating at least one specialist. The development of staff 191 variables is detailed in Supplemental Table 3. Lastly, we included each CEmONC signal 192 function, defined as having ever performed each of them before the survey, in the model.

193 Statistical analysis

194 In reporting descriptive statistics, we presented the proportion of facilities that had used ACS 195 within the past three months before the survey by country and facility characteristics. We also 196 reported the proportion of facilities that had performed each CEmONC signal function. In 197 presenting outcome distribution across countries, we presented the median and range from eight 198 countries, excluding Afghanistan, because of its different sampling strategy. To assess factors 199 associated with recent ACS use, we conducted mixed-effect log binomial regressions to report 200 adjusted relative risks (RR), including country as a fixed effect and sub-national regions within 201 each country as random intercepts. We performed bivariate regressions that also included a fixed 202 effect of country and random intercepts of sub-national regions. Modified Poisson regressions 203 (with a robust standard error) were conducted to explore country-specific associations for each 204 country.(25) This approach was chosen to obtain effect measures of relative risks and ensure 205 model convergence with smaller sample sizes compared to the pooled regression models. We did 206 not include sub-national divisions as random intercepts in within-country regressions. All 207 analyses were performed using R.

It is made available under a CC-BY 4.0 International license .

208 RESULTS

209 This study included 6,183 facilities of nine LMICs from ten SPA surveys. Across eight countries 210 (excluding Afghanistan), about one-third of facilities (median 30.5%; range 14.6% to 89.6%) 211 were in urban areas, whereas most (99.4%) facilities in Afghanistan were urban (Table 1). Most 212 facilities were public (median 83.6%; range 43.1% to 91.6%), followed by private for-profit 213 facilities (median 9.8%; range 3.6% to 24.7%) and private not-for-profit/mission or faith-based 214 facilities (median 8.7%; range 0.8% to 27.2%). Staffing of specialized professionals was 215 generally suboptimal. Across eight countries, fewer than one-fifth or one-fifth of facilities had at 216 least one medical doctor (median 17.3%; range 6.1% to 76.5%) or midwife (median 20.2%; 217 range 7.7% to 95.9%). In Afghanistan, 39.6% of the facilities had at least one medical doctor, 218 and most (93.4%) had at least one midwife. For the three countries that assessed the availability of obstetricians/gynecologists and pediatricians, fewer than 10% of the facilities had at least one 219 220 obstetrician/gynecologist (median 8.9%; range 7.5% to 16.7%) and pediatrician (median 7.5%; 221 range 5.1% to 12.5%). Similarly, only 9.1% (median; range 3.1% to 70.6%) of the facilities 222 among the six countries that surveyed specialists had at least one specialist. 223 *Recent ACS use.* The proportions of facilities that had used ACS within the past 3 months varied, 224 ranging from 4.0% in Tanzania to 27.4% in Ethiopia, with a median of 22.7% (Table 2). 225 Afghanistan had 59.4% of the facilities that used ACS recently. Recent ACS use also differed by 226 facility characteristics (Table 2). A larger proportion of urban facilities used ACS recently than 227 rural facilities (44.5% versus 21.1%). Facilities with injectable corticosteroids and a functional 228 ultrasound were more likely to use ACS in the past three months compared to those without. The 229 proportion of facilities that had recently used ACS increased by readiness tertile: 14.6% for the 230 lowest tertile, 21.9% for the middle, and 48% for the highest. Facilities with at least one medical

	Country and survey year									
Facility characteristics	Median (range) ¹	Afghanistan 2018-2019 (n=101)	Bangladesh 2017-2018 (n=822)	Nepal 2021 (n=807)	Haiti 2017-2018 (n=362)	DRC 2017-2018 (n=1354)	Ethiopia 2021-2022 (n=650)	Malawi 2013-2014 (n=542)	Senegal 2018& 2019 (n=593)	Tanzania 2014-2015 (n=952)
Location										
Urban (%)	30.5% (14.6% - 89.6%)	100 (99.4%)	326 (21.9%)	485 (43.3%)	145 (40.0%)	293 (21.8%)	391 (39.0%)	82 (15.1%)	542 (89.6%)	278 (14.6%)
Managing authority type (%)										
Public	83.6% (43.1% - 91.6%)	14 (8.2%)	682 (83.6%)	631 (91.6%)	156 (43.1%)	823 (61.9%)	560 (91.3%)	356 (65.5%)	537 (85.3%)	692 (83.6%)
Private for-profit	9.8% (3.6% - 24.7%)	71 (71.4%)	104 (11.6%)	154 (7.5%)	89 (24.7%)	154 (17.9%)	75 (7.9%)	25 (4.9%)	37 (12.1%)	70 (3.6%)
Private not-for-profit/mission or faith-based	8.7% (0.8% - 27.2%)	16 (20.4%)	36 (4.9%)	22 (0.8%)	52 (14.3%)	377 (20.2%)	15 (0.9%)	148 (27.2%)	19 (2.6%)	180 (12.5%)
Others	0 % (0% - 17.9%)	0 (0%)	0 (0%)	0 (0%)	65 (17.9%)	0 (0%)	0 (0%)	13 (2.5%)	0 (0%)	10 (0.3%)
Staff (%)										
Has at least one medical doctor	17.3% (6.1% - 76.5%)	56 (39.6%)	344 (27.1%)	166 (7.1%)	277 (76.5%)	852 (31.1%)	431 (23.2%)	59 (10.8%)	138 (11.3%)	238 (6.1%)
Has at least one midwife	20.2% (7.7% - 95.9%)	97 (93.4%)	121 (8.6%)	176 (7.7%)	277 (76.5%)	233 (7.9%)	252 (9.3%)	520 (95.9%)	461 (74.3%)	577 (30.6%)
Has at least one obstetrician or gynecologist ²	8.9% (7.5% - 16.7%)	-	213 (16.7%)	196 (8.9%)	-	-	191 (7.5%)	-	-	-
Has at least one pediatrician ²	7.5% (5.1% - 12.5%)	-	164 (12.5%)	168 (7.5%)	-	-	144 (5.1%)	-	-	-
Has at least one specialist ²	9.1% (3.1% - 70.6%)	86 (70.6%)	-	-	165 (45.5%)	107 (3.3%)	-	31 (5.7%)	89 (12.5%)	133 (3.1%)

¹ Median and range were obtained from eight countries excluding Afghanistan. ² Only Bangladesh 2017-2018, Nepal 2021, and Ethiopia 2021-2022 surveyed the availability of obstetricians or gynecologists, and pediatricians. Other countries surveyed the availability of specialists but did not survey specific types of staff.

	Proportion of facilities with	Biv	ariate regrssion ²		Multivariate regression ³			
	recent ACS use (%) ¹	relative risk (RR)	95% CI	p-value	Adjusted relative risk (aRR)	95% CI	p-value	
Country								
Afghanistan 2018-2019	59.4%	2.11	1.26 - 3.52	0.004	0.89	0.53 - 1.50	0.661	
Nepal 2021	8.2%	0.45	0.28 - 0.71	0.001	0.34	0.22 - 0.51	<0.001	
Haiti 2017-2018	23.6%	0.59	0.37 - 0.93	0.022	0.32	0.21 - 0.51	<0.001	
DRC 2017-2018	22.2%	1.05	0.74 - 1.49	0.795	0.76	0.53 - 1.07	0.113	
Ethiopia 2021-2022	27.4%	1.53	1.01 - 2.31	0.043	0.80	0.54 - 1.18	0.257	
Malawi 2013-2014	21.5%	0.44	0.26 - 0.73	0.002	0.53	0.32 - 0.87	0.012	
Senegal 2018 and 2019	23.4%	0.66	0.44 - 0.99	0.047	0.95	0.64 - 1.42	0.811	
Tanzania 2014-2015	4.0%	0.35	0.24 - 0.51	< 0.001	0.25	0.17 - 0.36	<0.001	
Bangladesh 2017-2018	23.2%	ref			ref			
Facility characteristics								
Location								
Urban <i>versus</i> rural ⁴	44.5% versus 21.1%	3.09	2.77 - 3.45	< 0.001	1.21	1.06 - 1.38	0.004	
Managing authority type								
Public	28.0%	ref			ref			
Private for-profit	43.0%	1.51	1.32 - 1.74	< 0.001	0.78	0.66 - 0.91	0.002	
Private not-for-profit/faith or mission-based	37.8%	1.48	1.29 - 1.70	< 0.001	0.85	0.73 - 0.99	0.039	
Others	19.5%	1.00	0.59 - 1.68	0.995	0.99	0.58 - 1.69	0.975	
Structural readiness								
Corticosteroid availability versus unavailability ⁵	45.1% versus 18.9%	2.72	2.43 - 3.04	< 0.001	1.14	1.01 - 1.29	0.032	
Ultrasound availability versus unavailability ⁵	60.9% versus 19.3%	5.00	4.48 - 5.57	< 0.001	1.26	1.10 - 1.45	0.001	
Readiness tertile ⁶								
High	48.0%	7.52	6.37 - 8.89	< 0.001	1.91	1.58 - 2.30	<0.001	
Middle	21.9%	2.27	1.91 - 2.70	< 0.001	1.23	1.03 - 1.48	0.021	
Low	14.6%	ref			ref			
Staffing ⁷								
At least one medical doctor versus no medical doctor ⁸	56.5% versus 13.2%	5.99	5.33 - 6.74	<0.001	1.43	1.22 – 1.67	<0.001	
At least one midwife versus no midwife8	38.8% versus 25.1%	3.17	2.84 - 3.55	<0.001	1.23	1.08 - 1.40	0.002	
At least one specialist versus no specialist8	61.8% versus 23.4%	4.37	3.91 - 4.90	<0.001	1.21	1.05 – 1.39	0.009	
CEmONC signal functions ⁹								
Ever provide parenteral antibiotics versus never	37.8% versus 6.1%	7.18	5.70 - 9.05	< 0.001	1.48	1.15 - 1.90	0.002	
Ever provide parenteral oxytocin versus never	33.1% versus 5.5%	8.73	5.80 - 13.14	<0.001	1.77	1.15 - 2.73	0.010	
Ever provide parenteral anticonvulsants versus never	46.2% versus 11.5%	5.40	4.75 - 6.14	<0.001	1.65	1.43 – 1.91	<0.001	
Ever perform assisted vaginal delivery versus never	37.1% versus 12.6%	3.44	2.91 - 4.06	<0.001	1.12	0.93 - 1.34	0.224	
Ever perform manual removal of placenta versus never	38.2% versus 7.2%	5.62	4.57 - 6.91	<0.001	1.98	1.58 - 2.47	<0.001	
Ever perform removal of retained products versus never	39.8% versus 11.8%	3.74	3.24 - 4.32	< 0.001	1.39	1.19 – 1.63	<0.001	
Ever perform neonatal resuscitation versus never	36.7% versus 4.4%	9.46	7.06 - 12.66	<0.001	2.62	1.93 - 3.55	<0.001	
Ever perform Cesarean sections versus never	63.5% versus 13.1%	8.01	7.12 - 9.01	<0.001	1.85	1.53 - 2.24	<0.001	
Ever provide blood transfusion versus never	63.8% versus 15.1%	6.69	5.99 - 7.47	<0.001	1.37	1.16 – 1.63	<0.001	

¹ Recent ACS use was defined as using ACS within the past 3 months. For each country, the proportions were calculated considering facility sampling weight. ² Risk ratios (RR) were derived from bivariate regressions that included each independent variable separately, country fixed effects, and sub-national divisions as random intercepts. ³ Adjusted risk ratios (aRR) were derived from mixed effect log binomial regression model that included all independent variables, country fixed effects, and sub-national regions as random intercepts.

⁴ Rural is the reference level.

⁵Unavailability is the reference level.

⁶ Readiness tertiles refer to country-specific readiness tertiles, calculated by the available numbers of equipment, diagnostics, medicines and commodities, and guidelines.
 ⁷ These binary variables indicate facilities having at least one medical doctor, midwife, or specialist, which were constructed based on the surveyed staff types for each SPA.

⁸No medical doctor, no midwife, or no specialist is the reference level.

⁹Facilities that never performed each CEmONC signal function were viewed as the reference level

It is made available under a CC-BY 4.0 International license .

doctor, midwife, or specialist were more likely to administer ACS recently than those without:
56.5% versus 13.2%, 38.8% versus 25.1%, 61.8% versus 23.4%, respectively. In addition, higher
proportions of facilities that had provided any of the CEmONC services used ACS recently than
those that had never performed the signal function.

235 *CEmONC signal functions past performance.* One-fifth of the facilities (19.0%, median of eight 236 countries) had ever performed all nine CEmONC signal functions, compared to two-fifths 237 (40.6%) in Afghanistan. Across eight countries and among nine signal functions, Cesarean 238 sections and the provision of blood transfusions were performed in the smallest proportion of 239 facilities since only CEmONC facilities were designated for these two services. Among seven 240 BEmONC signal functions, the provision of parenteral anticonvulsant was performed in the 241 smallest proportion of facilities (median 37.6%), while oxytocin administration was performed in 242 the largest proportion (median 94.3%) (Figure 1). Ethiopia was the only country among the eight countries where more than 80% of the facilities had performed each BEmONC signal function. 243

Figure 1. Proportion of facilities that have performed nine Comprehensive Emergency Obstetricand Newborn Care (CEmONC) signal functions

246 *Factors affecting recent ACS use.* Table 2 details the results of mixed-effect log binomial

247 regressions, showing that facility characteristics, structural readiness, and past performance of

248 CEmONC are associated with recent ACS use. Urban facilities had 21% higher recent ACS use

than rural facilities (RR 1.21, 95% CI 1.06–1.39). Private for-profit facilities and private not-for-

- 250 profit facilities, compared to public facilities, were associated with lower recent ACS use,
- although both types showed higher recent ACS use in bivariate regressions. The availability of
- injectable corticosteroids and ultrasound were associated with increased recent ACS use by 14%

It is made available under a CC-BY 4.0 International license .

253 (RR 1.14, 95% CI 1.01–1.29) and 26% (RR 1.26, 95% CI 1.10–1.45), respectively. Facilities in

the highest readiness tertile had 91% higher recent ACS use than those in the lowest (RR 1.91,

255 95% CI 1.58–2.30). Staffing types affected recent ACS use: facilities with at least one medical

doctor, midwife, or specialist had increased recent ACS use by 43% (RR 1.43, 95% CI 1.22–

257 1.67), 23% (RR 1.23, 95% CI 1.08 to 1.40), and 21% (RR 1.21, 95% CI 1.05–1.39), respectively.

- 258 Lastly, past performance of each CEmONC signal function, except for assisted vaginal
- 259 deliveries, was significantly associated with more recent ACS use, with performing neonatal
- resuscitation having the largest effect (RR 2.62, 95%CI 1.93–3.56). Country-specific regressions
- were detailed in **Supplemental Table 4**.

262 **DISCUSSION**

263 Our study showed the complex relationships between recent ACS utilization and facility-level

factors. We found that recent ACS use was significantly higher in urban facilities, facilities with

injectable corticosteroids and ultrasound available, facilities with the highest level of readiness,

and facilities that had performed CEmONC services.

A consistent corticosteroid stock is fundamental for promoting ACS use.(26, 27) Our previous

work found that only one-fourth of the facilities that provided antenatal care or delivery services

in the same eight countries (excluding Afghanistan) had injectable corticosteroids available.(23)

270 Interestingly, this study found a relatively small effect of corticosteroid availability (RR 1.14).

As we used the availability of corticosteroids under the medicines for non-communicable

diseases as a proxy, this approach might have overestimated their availability in maternal care.

273 Thus, the effect size, while still statistically significant, is not as large as expected. The

- 274 phenomenon might be explained by the idea that corticosteroid unavailability only partially
- 275 contributed to the barrier to proper ACS use. In other words, while the availability of

276	corticosteroids is essential, it does not guarantee their use. Our previous study also revealed the
277	gap between corticosteroid availability and ACS use.(23) We suspect that the effect of
278	corticosteroid availability might be offset by other factors, such as providers' insufficient
279	knowledge. Providers play a critical role in effective ACS utilization, including their awareness
280	and knowledge of ACS, abilities to identify eligible women, and their perceived risks and
281	benefits of ACS.(14, 15, 26, 28, 29) Similarly, the concern about the gap between availability
282	and utilization also applies to facility readiness, meaning that high structural readiness does not
283	always translate into good clinical practices; for example, the volume of delivery service of a
284	facility is related to its provision of services for managing obstetric emergencies.(30) To
285	triangulate factors affecting ACS use, by summarizing previous evidence, we proposed a
286	framework for effective and safe ACS use at four levels (Figure 2).
287	Figure 2. Framework for safe and effective antenatal corticosteroid utilization at four levels
288	While we found an association between ultrasound availability and recent ACS use, the effect
289	size is relatively small, and the interpretation requires caution. First, ultrasound in early
290	pregnancy, the gold standard for accurate GA dating, is uncommon in low-resource countries.
291	Although its use is increasing in these countries (31), our previous work showed that only 7.3%
292	of facilities that provided antenatal care or delivery services in eight LMICs had a functional
293	ultrasound at the time of the survey.(23) A Bangladesh household survey of 700 women found
294	that only 11% received an ultrasound examination in the first trimester.(32) Another critical
295	point is that many women in LMICs initiate their antenatal care late (33, 34), resulting in missed
296	opportunities. The prevalence of early antenatal care visits, defined as initiating before 14 weeks
297	of gestation, was only 24.0% in LMICs versus 81.9% in high-income countries.(33) The limited
298	ultrasound availability and late presentation to antenatal care might partly explain the small

It is made available under a CC-BY 4.0 International license .

effect size in our findings. Additionally, the ultrasound measurement we used only reflected its
availability at the time of the survey, which may not fully represent its availability in women's
first antenatal care visits, whether in the same facility or another.

302 Notably, this study identified strong associations between CEmONC signal functions and recent 303 ACS use. There are a few potential explanations. First, CEmONC signal functions are meant to 304 manage obstetric emergencies, which often involve a high likelihood of preterm labor. In these 305 cases, providers should adopt a comprehensive approach to both save mothers' lives and improve 306 preterm newborn outcomes, including ACS administration to eligible women. For example, 307 studies have demonstrated the benefits of administering ACS to women with severe 308 preeclampsia. (35, 36) Second, this finding highlights the importance of provider knowledge, 309 skills, and competence. The effect sizes for some CEmONC signal functions (RR 2.62 for 310 neonatal resuscitation, RR 1.98 for performing manual removal of placenta, and 1.85 for 311 performing Cesarean sections) are much larger than that for corticosteroid availability (RR 1.14). 312 In other words, by controlling for all other factors, facilities with providers who have performed 313 neonatal resuscitations are much more likely to administer ACS. This finding suggests that past 314 performance of CEmONC signal functions reflects two critical aspects: first, providers' 315 knowledge, skills, and competence to perform the services, and second, the availability of a 316 minimal level of medicines and equipment.(21) These two are crucial for delivering effective 317 care; missing either will not work. Our findings have strong policy implications. Policymakers 318 should prioritize provider training in emergent obstetric care while improving facility readiness 319 and creating environments that encourage good clinical practice because in-service training alone 320 does not deliver long-lasting effects.(37)

It is made available under a CC-BY 4.0 International license .

321 Our study has a few limitations. First, the countries in our sample differed in many aspects.(23) 322 For example, national guidelines about ACS use vary. Some countries, such as Tanzania and 323 Ethiopia, recommend administering ACS at the primary level of care, followed by referrals.(38-324 40) We recommend careful interpretations in any attempt to compare across countries. Second, 325 there is a temporal discrepancy between corticosteroid availability and recent ACS use, with the 326 former measured at the time of the survey and the latter defined as having provided ACS in the 327 past 3 months before the survey. In addition, ACS utilization in the past 3 months does not 328 represent the appropriateness of ACS use, meaning that the correct doses are given to eligible 329 pregnant women at the right times. Third, we are aware of the collinearity between some 330 independent variables in the regressions. For instance, facilities in the highest readiness tertile 331 are likely to have the equipment, medicines, or staff required for CEmONC signal functions. 332 This study confirmed the complexity of factors affecting ACS utilization in LMICs. While 333 corticosteroid availability is fundamental, providers' knowledge and skills - reflected by the past 334 performance of CEmONC services in our findings-affect safe and effective ACS administration. Policymakers should examine factors contributing to low ACS use at various levels and identify 335 336 strategies to promote the implementation of this life-saving intervention. 337 Disclosure of relationships and activities: All authors have completed the ICMJE uniform 338 disclosure form at www.icmje.org/coi disclosure.pdf and declared no support from any 339 organization for submitted work; no financial relationships with any organization that might have

an interest in the submitted work in the previous three years; no other relationships or activities

that could appear to have influenced the submitted work.

It is made available under a CC-BY 4.0 International license .

342 Ethical approval: This study was determined by the George Washington University Committee
343 on Human Research, Institutional Review Board to be research that is exempt from IRB review
344 (IRB# NCR235271).

345 Author contributions: WCY, CA, VYF, and ESR conceptualized and designed the study and

346 proposed an analysis plan. WCY conducted the analysis. CA, VYF, NBA, FMAA, and ESR

347 provided inputs to the analysis results and suggested additional analyses. NBA reviewed the

348 statistical codes and provided feedback. WCY, CA, and ESR drafted the manuscript. NBA and

349 FMAA provided insights based on their expertise about the context and suggested areas for

discussion. All authors critically reviewed the manuscript, made edits, and approved the final

351 version of the manuscript for submission.

352 Funding and sponsorship: This study was not funded.

353 Supporting information: Supplementary file

REFERENCES

1. The World Health Organization. 2022 WHO recommendations on ACS to improve preterm birth outcomes. 2022.

2. Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS. Society for Maternal-Fetal Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016. American journal of obstetrics and gynecology. 2021;225(5):B36-b42.

3. Norman J, Shennan A, Jacobsson B, Stock SJ, Birth FWGfP. FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm. Int J Gynaecol Obstet. 2021;155(1):26-30.

4. EI-Sayed YY, Borders AEB, Gyamfi-Bannerma C. ACOG committee opinion, Antenatal Corticosteroid Therapy for Fetal Maturation The American College of Obstetricians and Gynecologists. 2017;130(2):e102-e9.

5. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020;12(12):Cd004454.

6. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. The Lancet Global health. 2019;7(1):e37-e46.

7. The World Health Organization. Born too soon: decade of action on preterm birth. 2023.

8. Hall M, Valencia CM, Soma-Pillay P, Luyt K, Jacobsson B, Shennan A. Effective and simple interventions to improve outcomes for preterm infants worldwide: The FIGO PremPrep-5 initiative. Int J Gynaecol Obstet. 2024;165(3):929-35.

9. Zahroh RI, Hazfiarini A, Eddy KE, Vogel JP, Tunçalp Ö, Minckas N, et al. Factors influencing appropriate use of interventions for management of women experiencing preterm birth: A mixed-methods systematic review and narrative synthesis. PLoS medicine. 2022;19(8):e1004074.

10. Aleman A, Cafferata ML, Gibbons L, Althabe F, Ortiz J, Sandoval X, et al. Use of antenatal corticosteroids for preterm birth in Latin America: providers knowledge, attitudes and practices. Reprod Health. 2013;10:4.

11. Liu G, Segrè J, Gülmezoglu A, Mathai M, Smith JM, Hermida J, et al. Antenatal corticosteroids for management of preterm birth: a multi-country analysis of health system bottlenecks and potential solutions. BMC pregnancy and childbirth. 2015;15 Suppl 2(Suppl 2):S3.

12. Greensides D, Robb-McCord J, Noriega A, Litch JA. Antenatal Corticosteroids for Women at Risk of Imminent Preterm Birth in 7 sub-Saharan African Countries: A Policy and Implementation Landscape Analysis. Global health, science and practice. 2018;6(4):644-56.

13. The World Health Organization. The WHO Model List of Essential Medicines 23rd list 2023.

14. Levison J, Nanthuru D, Chiudzu G, Kazembe PN, Phiri H, Ramin SM, et al. Qualitative assessment of attitudes and knowledge on preterm birth in Malawi and within country framework of care. BMC pregnancy and childbirth. 2014;14:123.

15. Antony KM, Levison J, Suter MA, Raine S, Chiudzu G, Phiri H, et al. Qualitative assessment of knowledge transfer regarding preterm birth in Malawi following the implementation of targeted health messages over 3 years. International journal of women's health. 2019;11:75-95.

16. Townsend R, Calvert C. Antenatal corticosteroids in adequately equipped facilities in low-resource settings. The Lancet Global health. 2022;10(10):e1379-e80.

17. Sultana S, Vogel JP, Oladapo OT. The efficacy of antenatal corticosteroids to improve preterm newborn outcomes in low-resource countries: Are we there yet? BJOG : an international journal of obstetrics and gynaecology. 2023.

18. The World Health Organization. Monitoring Emergency Obstetric Care: a Handbook. 2009.

19. Otolorin E, Gomez P, Currie S, Thapa K, Dao B. Essential basic and emergency obstetric and newborn care: from education and training to service delivery and quality of care. Int J Gynaecol Obstet. 2015;130 Suppl 2:S46-53.

20. Campbell OM, Graham WJ. Strategies for reducing maternal mortality: getting on with what works. Lancet (London, England). 2006;368(9543):1284-99.

21. Stierman EK, Ahmed S, Shiferaw S, Zimmerman LA, Creanga AA. Measuring facility readiness to provide childbirth care: a comparison of indices using data from a health facility survey in Ethiopia. BMJ Glob Health. 2021;6(10).

22. The DHS program. The Demographic and Health Surveys, The Service Provision Assessment USAID; [Available from: <u>https://dhsprogram.com/methodology/Survey-Types/SPA.cfm</u>.

23. Yang W-C, Arsenault C, Fan VY, Leslie HH, Farooq F, Pembe AB, et al. Antenatal corticosteroids for pregnant women at risk of preterm labor in low- and middle-income countries: utilization and facility readiness. medRxiv. 2024:2024.07.31.24310863.

24. The DHS program. Continuous Service Provision Assessment.

25. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. American Journal of Epidemiology. 2004;159(7):702-6.

26. Kaplan HC, Sherman SN, Cleveland C, Goldenhar LM, Lannon CM, Bailit JL. Reliable implementation of evidence: a qualitative study of antenatal corticosteroid administration in Ohio hospitals. BMJ quality & safety. 2016;25(3):173-81.

27. Smith JM, Gupta S, Williams E, Brickson K, Ly Sotha K, Tep N, et al. Providing antenatal corticosteroids for preterm birth: a quality improvement initiative in Cambodia and the Philippines. International journal for quality in health care : journal of the International Society for Quality in Health Care. 2016;28(6):682-8.

28. Leviton LC, Baker S, Hassol A, Goldenberg RL. An exploration of opinion and practice patterns affecting low use of antenatal corticosteroids. American journal of obstetrics and gynecology. 1995;173(1):312-6.

29. Mc Goldrick EL, Crawford T, Brown JA, Groom KM, Crowther CA. Identifying the barriers and enablers in the implementation of the New Zealand and Australian Antenatal Corticosteroid Clinical Practice Guidelines. BMC health services research. 2016;16(1):617.

30. Kruk ME, Leslie HH, Verguet S, Mbaruku GM, Adanu RMK, Langer A. Quality of basic maternal care functions in health facilities of five African countries: an analysis of national health system surveys. The Lancet Global health. 2016;4(11):e845-e55.

31. Stewart KA, Navarro SM, Kambala S, Tan G, Poondla R, Lederman S, et al. Trends in Ultrasound Use in Low and Middle Income Countries: A Systematic Review. International journal of MCH and AIDS. 2020;9(1):103-20.

32. Siddique AB, Perkins J, Mazumder T, Haider MR, Banik G, Tahsina T, et al. Antenatal care in rural Bangladesh: Gaps in adequate coverage and content. PLoS One. 2018;13(11):e0205149.

33. Moller AB, Petzold M, Chou D, Say L. Early antenatal care visit: a systematic analysis of regional and global levels and trends of coverage from 1990 to 2013. The Lancet Global health. 2017;5(10):e977-e83.

34. Gebresilassie B, Belete T, Tilahun W, Berhane B, Gebresilassie S. Timing of first antenatal care attendance and associated factors among pregnant women in public health institutions of Axum town, Tigray, Ethiopia, 2017: a mixed design study. BMC pregnancy and childbirth. 2019;19(1):340.

35. Briceño-Pérez C, Reyna-Villasmil E, Vigil-De-Gracia P. Antenatal corticosteroid therapy: Historical and scientific basis to improve preterm birth management. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2019;234:32-7.

36. Magann EF, Haram K, Ounpraseuth S, Mortensen JH, Spencer HJ, Morrison JC. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Acta obstetricia et gynecologica Scandinavica. 2017;96(4):395-409.

37. Arsenault C, Rowe SY, Ross-Degnan D, Peters DH, Roder-DeWan S, Kruk ME, et al. How does the effectiveness of strategies to improve healthcare provider practices in low-income and middle-income countries change after implementation? Secondary analysis of a systematic review. BMJ quality & safety. 2022;31(2):123-33.

38. Ministry of Health and Social Welfare the United Republic of Tanzania. Administration of Antenatal Corticosteroids in Pre-Term Labour. 2015.

39. Ministry of Health Ethiopia. Obstetrics Management Protocol for Hospitals. 2021.
40. Ministry of Health Ethiopia. Obstetrics Management Protocol for Health Centers.
2021.

Provide parenteral antibiotics —	85.4%	45.2%	57.2%	86.7%	80.3%	94.3%	88.7%	75%	54.5%	77.7%
Provide parenteral oxytocin	91.5%	61.7%	94.4%	94.2%	96%	98.6%	98.5%	92.4%	90.2%	94.3%
Provide parenteral anticonvulsants	68.6%	25.7%	29.8%	56%	39%	81.5%	78.4%	36.3%	29.5%	37.6%
Perform assisted vaginal delivery	85%	57.9%	16%	92.8%	81.4%	95.6%	64.2%	98.1%	75.5%	78.4%
Perform manual removal of placenta	80.4%	72.4%	59.9%	79.2%	82.2%	94.2%	71.5%	49.3%	58.5%	72%
Perform removal of retained products	87.4%	48.7%	45%	72.7%	65%	87.3%	50.7%	73.3%	53.2%	59.1%
Perform neonatal resuscitation	84.7%	67.4%	60.2%	73.2%	79.6%	91.7%	95.2%	76.9%	76.5%	76.7%
Perform Cesarean section	87.4%	17.8%	9%	29.2%	24.4%	10.7%	12.6%	8.3%	5.9%	11.6%
Provide blood transfusion	74.4%	13.2%	9.9%	31.2%	20.9%	10.2%	14.8%	4.6%	5.7%	11.7%
	AFG18	BD17	NP21	HT17	DRC17 Country and	ET21 survey year	MW13	SN1819	TZ14	median*

Proportion level

0-20% 21-40% 41-60% 61-80% 81-100%

AFG18: Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Hall 2017-2018; DRC17: the Democratic Republic of Congo 2017-2018; ET21: Ethiopia 20121-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015; median*: median across eight countries except Afghanistan

Figure1



Figure2